A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)
Completed
Merck Sharp & Dohme Corp.
Phase 3
2006-02-01
This study will investigate the safety and efficacy of raltegravir as a therapy for Human
Immunodeficiency Virus (HIV)-infected patients failing current therapy with 3-class antiviral
resistance.
A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)
Completed
Merck Sharp & Dohme Corp.
Phase 3
2006-02-01
This study will investigate the safety and efficacy of raltegravir as a therapy for
HIV-infected patients failing current therapy with 3-class antiviral resistance.
Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses
Completed
Janssen-Cilag Tibotec
Phase 2
2007-05-01
The purpose of this study is to look at the safety and efficacy of a combination of 3 new
antiretroviral drugs: darunavir, etravirine and MK-0518 (raltegravir) in patients who have
multi-resistant viruses and limited treatment options. An optimized background regimen that
may include nucleoside reverse transcriptase inhibitors (NRTIs) and enfuvirtide can be added,
if possible, to this combination. Patients will undergo treatment for 48 weeks and
virological efficacy will be evaluated at week 24.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.